We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CABAZITAXEL-TEVA (Teva Pharma Australia Pty Ltd)
Product name
CABAZITAXEL-TEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
253 working days (255)
Active ingredients
cabazitaxel ethyl acetate solvate
Registration type
New generic medicine
Indication
CABAZITAXEL-TEVA (concentrated solution for injection) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.